Niagen Bioscience (NAGE) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Niagen Bioscience (NAGE) overview

Niagen Bioscience (NAGE) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 129m and operating profit of USD 16.3m; the year-end share price was 6.36 USD and market capitalisation was USD 507m. Niagen Bioscience is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Niagen Bioscience's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 76.5mFY 2025
Share price6.36 USDFY 2025 year end
RevenueUSD 129mFY 2025
Operating profitUSD 16.3mFY 2025
Net earningsUSD 17.4mFY 2025
Market capitalisationUSD 507mFY 2025 year end

About Niagen Bioscience

Niagen Bioscience develops and commercializes products based on nicotinamide riboside, a form of vitamin B3 and precursor to NAD+. Its offerings include food-grade Niagen as a dietary and food ingredient, Tru Niagen dietary supplements for consumers, and Niagen Plus products featuring pharmaceutical-grade Niagen. It also supplies pharmaceutical-grade Niagen to outsourcing facilities and compounding pharmacies for prescription injectable formulations.

Generate the Niagen Bioscience report

Niagen Bioscience is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Niagen Bioscience and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Niagen Bioscience

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.